Much of the talk these days regarding HR technology revolves around big data, wearable devices and bring-your-own-device policies. Such current technological concerns could be mere child’s play compared to cyberconsciousness and how it could alter the workforce of the future. This obscure concept is brought to you courtesy of Martine Rothblatt, an unrelenting force in business.
Another one to file under the Science is Awesome category: Johns Hopkins University’s Applied Physics Laboratory has engineered prosthetic arms that can be controlled with the mind.
Much like the American Dream, entrepreneurship is a national ideal of the United States representing a belief that prosperity and success can be achieved through hard, tireless work. Developing a technological innovation that will change the world for the better is what it’s all about these days, especially for young people trying to make a name for themselves on college campuses. Students arrive on school grounds driven by two thoughts – fear of failure and desire for success – both of which naturally lead down the road to entrepreneurship.
Boards aren’t working. It’s been more than a decade since the first wave of post-Enron regulatory reforms and, despite a host of guidelines from independent watchdogs such as the International Corporate Governance Network, most boards aren’t delivering on their core mission: providing strong oversight and strategic support for management’s efforts to create long-term value.
The Swiss firm, which this week filed a melanoma combination drug for US approval, spent $10bn on research into new products, ahead of rivals such as Novartis, which spent $9.8bn and the $8.2bn spent by Johnson & Johnson (J&J).
Shareholders in British drugmaker GlaxoSmithKline (GSK.L) have approved a planned deal with Switzerland’s Novartis (NOVN.VX), which will see the two pharmaceutical groups trade more than $20 billion (12.7 billion pounds) of assets.
A coalition of geneticists and computer programmers calling itself the Global Alliance for Genomics and Health is developing protocols for exchanging DNA information across the Internet. The researchers hope their work could be as important to medical science as HTTP, the protocol created by Tim Berners-Lee in 1989, was to the Web.
United Therapeutics (Nasdaq: UTHR) announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D’s compensation program.
University of Massachusetts President Robert Caret will take over as University System of Maryland’s fourth chancellor in July.
Let’s be clear: Martine Rothblatt is just plain more of a lawyer than anybody else in this town.
The 60-year-old grandmother and CEO of United Therapeutics, the Silver Spring-based biotech she founded to help save her younger daughter’s life, banked $38 million last year. It made her the nation’s highest-paid female executive. It also made her the nation’s highest-paid transgendered person, as she had sex reassignment surgery in 1994.
